<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>HYDROXOCOBALAMIN- hydroxocobalamin acetate injection, solution </strong><br>REMEDYREPACK INC. <br></p></div>
<h1>HYDROXOCOBALAMIN INJECTION USP
Rx only</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-1"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First"></p>
<p>Hydroxocobalamin injection is a sterile solution of hydroxocobalamin for intramuscular administration.</p>
<p>Each mL contains: Hydroxocobalamin Acetate equivalent to 1000 mcg Hydroxocobalamin, Sodium Acetate Anhydrous 0.2 mg, Glacial Acetic Acid 0.442 mg, Sodium Chloride 8.2 mg, with Methylparaben 1.5 mg and Propylparaben 0.2 mg as preservatives, in Water for Injection q.s. Additional Glacial Acetic Acid and/or Sodium Acetate may have been used to adjust pH. pH range is 3.5 to 5.0.</p>
<p>Hydroxocobalamin appears as dark red orthorhombic needles or as an amorphous or crystalline red powder. It is very hygroscopic in the anhydrous form, and moderately soluble in water. It has a molecular weight of 1346.37. The vitamin B<span class="Sub">12</span> coenzymes are very unstable in light. Hydroxocobalamin shares the cobalamin molecular structure with cyanocobalamin.</p>
<p>The chemical name is α-(5,6-dimethylbenzimidazoly) hydroxocobamide. The empirical formula is C<span class="Sub">62</span>H<span class="Sub">89</span>CoN<span class="Sub">13</span>O<span class="Sub">15</span>P and its structural formula is:</p>
<p><img alt="MM1" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d35ad609-70d3-4eb2-8276-c9631ca815d1&amp;name=MM1.jpg"></p>
<p></p>
<p>The cobalt content is 4.34%.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-2"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First"></p>
<p>Vitamin B<span class="Sub">12</span> is essential to growth, cell reproduction, hematopoiesis, nucleoprotein and myelin synthesis.</p>
<p>Fifty percent of the administered dose of hydroxocobalamin disappears from the injection site in 2.5 hours. Hydroxocobalamin is bound to plasma proteins and stored in the liver. It is excreted in the bile and undergoes some enterohepatic recycling. Within 72 hours after injection of 500 to 1000 mcg of hydroxocobalamin, 16 to 66 percent of the injected dose may appear in the urine. The major portion is excreted within the first 24 hours.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-3"></a><p></p>
<h1>INDICATIONS &amp; USAGE</h1>
<p class="First"></p>
<ol>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">Pernicious anemia</span>, both uncomplicated and accompanied by nervous system involvement.</p></li>
<li><p class="First">Dietary deficiency of Vitamin B<span class="Sub">12</span>, occurring in strict vegetarians and in their breast-fed infants. (Isolated vitamin B<span class="Sub">12</span> deficiency is very rare).</p></li>
<li><p class="First"><span class="product-label-link" type="condition" conceptid="194993" conceptname="Intestinal malabsorption">Malabsorption</span> of vitamin B<span class="Sub">12</span>, resulting from structural or functional damage to the stomach, where intrinsic factor is secreted or to the ileum, where intrinsic factor facilitates vitamin B<span class="Sub">12</span> absorption. These conditions include tropical <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">sprue</span>, and <span class="product-label-link" type="condition" conceptid="194992" conceptname="Celiac disease">nontropical sprue</span> (idiopathic <span class="product-label-link" type="condition" conceptid="200146" conceptname="Pancreatic steatorrhea">steatorrhea</span>, gluten-induced enteropathy). <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">Folate deficiency</span> in these patients is usually more severe than vitamin B<span class="Sub">12</span> deficiency.</p></li>
<li>
<p class="First">Inadequate secretion of intrinsic factor, resulting from lesions that destroy the gastric mucosa (ingestion of corrosives, extensive neoplasia), and a number of conditions associated with a variable degree of gastric <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span> (such as <span class="product-label-link" type="condition" conceptid="374919" conceptname="Multiple sclerosis">multiple sclerosis</span>, certain <span class="product-label-link" type="condition" conceptid="31821" conceptname="Disorder of endocrine system">endocrine disorders</span>, <span class="product-label-link" type="condition" conceptid="4146209" conceptname="Iron deficiency">iron deficiency</span>, and subtotal gastrectomy). Total gastrectomy always produces vitamin B<span class="Sub">12</span> deficiency.</p>
<p>Structural lesions leading to vitamin B<span class="Sub">12</span> deficiency include regional <span class="product-label-link" type="condition" conceptid="4203614" conceptname="Ileitis">ileitis</span>, ileal resections, malignancies, etc.</p>
</li>
<li>
<p class="First">Competition for Vitamin B<span class="Sub">12</span> by intestinal parasites or bacteria.</p>
<p>The fish tapeworm (Diphyilobothrium latum) absorbs huge quantities of vitamin B<span class="Sub">12</span> and infested patients often have associated gastric <span class="product-label-link" type="condition" conceptid="4028206" conceptname="Atrophy">atrophy</span>. The blind-loop syndrome may produce deficiency of Vitamin B<span class="Sub">12</span> or folate.</p>
</li>
<li><p class="First">Inadequate utilization of vitamin B<span class="Sub">12</span>. This may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.</p></li>
<li><p class="First">For the Schilling Test.</p></li>
</ol>
<p></p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-4"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"></p>
<p><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any component of this medication.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-5"></a><p></p>
<h1>WARNINGS</h1>
<p class="First"></p>
<p>Avoid the intravenous route.</p>
<p>Folic acid is not a substitute for vitamin B<span class="Sub">12</span> although it may improve vitamin B<span class="Sub">12</span> deficient <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>. Exclusive use of folic acid in treating vitamin B<span class="Sub">12</span> deficient <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span> could result in progressive and irreversible neurologic damage.</p>
<p>Blunted or impeded therapeutic response to vitamin B<span class="Sub">12</span> may be due to such conditions as <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">uremia</span>, drugs having bone marrow suppressant properties such as chloramphenicol, and concurrent iron or <span class="product-label-link" type="condition" conceptid="4101280" conceptname="Folic acid deficiency">folic acid deficiency</span>.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-6"></a><p></p>
<h1>PRECAUTIONS</h1>
<p class="First"></p>
<p>The validity of diagnostic vitamin B<span class="Sub">12</span> or folic acid blood assays could be compromised by medications, and this should be considered before relying on such tests for therapy.</p>
<p>Vitamin B<span class="Sub">12</span> is not a substitute for folic acid and since it might improve folic acid deficient <span class="product-label-link" type="condition" conceptid="435789" conceptname="Megaloblastic anemia">megaloblastic anemia</span>, indiscriminate use of vitamin B<span class="Sub">12</span> could mask the true diagnosis.</p>
<p><span class="product-label-link" type="condition" conceptid="437833" conceptname="Hypokalemia">Hypokalemia</span> and <span class="product-label-link" type="condition" conceptid="4280071" conceptname="Thrombocytosis">thrombocytosis</span> could occur upon conversion of severe megaloblastic to normal erythropoiesis with B<span class="Sub">12</span> therapy. Therefore, serum potassium levels and the platelet count should be monitored carefully during therapy.</p>
<p>Vitamin B<span class="Sub">12</span> deficiency may suppress the signs of <span class="product-label-link" type="condition" conceptid="135214" conceptname="Polycythemia vera">polycythemia vera</span>. Treatment with vitamin B<span class="Sub">12</span> may unmask this condition.</p>
<p></p>
<p></p>
<p>Studies of carcinogenicity, mutagenesis, or impairment of fertility have not been performed with hydroxocobalamin.</p>
<p></p>
<p></p>
<p><span class="Italics">Teratogenic Effects:</span> Pregnancy Category C: Animal reproduction studies have not been conducted with hydroxocobalamin. It is also not known whether hydroxocobalamin can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Hydroxocobalamin should be given to a pregnant woman only if clearly needed.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-7"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"></p>
<p>Mild transient <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, transitory <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">exanthema</span>, feeling of <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of entire body, and <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>.</p>
<p>A few patients may experience <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> after injection of hydroxocobalamin.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-8"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"></p>
<p>The intravenous LD<span class="Sub">50</span> of hydroxocobalamin in mice is greater than 50 mL/kg.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-9"></a><p></p>
<h1>DOSAGE &amp; ADMINISTRATION</h1>
<p class="First"></p>
<p>Protect from light.</p>
<p>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.</p>
<p>Hydroxocobalamin injection should be given only intramuscularly.</p>
<p>In patients with Addisonian <span class="product-label-link" type="condition" conceptid="432295" conceptname="Pernicious anemia">Pernicious Anemia</span>, parenteral therapy with vitamin B<span class="Sub">12</span> is the recommended method of treatment and will be required for the remainder of the patient’s life. Oral therapy is not dependable. In other patients with vitamin B<span class="Sub">12</span> deficiency, the duration of therapy and route of administration will depend upon the cause and whether or not it is reversible.</p>
<p>Confirmatory diagnostic studies should be performed prior to initiating therapy, if possible, and the patient should be followed with appropriate studies to demonstrate hematologic improvement (Hgb, hematocrit, RBC, reticulocyte count). A diagnostic trial utilizing physiologic doses of vitamin B<span class="Sub">12</span> (1 mcg daily) and observing daily reticulocyte counts after establishing a baseline may also be performed. The observation of <span class="product-label-link" type="condition" conceptid="4261785" conceptname="Reticulocytosis">reticulocytosis</span> which usually occurs between the third and tenth day of therapy confirms the diagnosis of vitamin B<span class="Sub">12</span> deficiency.</p>
<p>In seriously ill patients it may be advisable to administer both vitamin B<span class="Sub">12</span> and folic acid while awaiting the results of distinguishing laboratory studies. It is not necessary to withhold vitamin B<span class="Sub">12</span> therapy until the precise cause of B<span class="Sub">12</span> deficiency is established since absorption studies can be performed at any time.</p>
<p>Serum potassium should be closely observed the first 48 hours and potassium should be administered if necessary.</p>
<p></p>
<p></p>
<p>Thirty mcg daily for 5 to 10 days followed by 100 to 200 mcg monthly injected intramuscularly. If the patient is critically ill, or has neurologic disease, an infectious disease or <span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">hyperthyroidism</span>, considerably higher doses may be indicated. However, current data indicate that the optimum obtainable neurologic response may be expected with a dosage of vitamin B<span class="Sub">12</span> sufficient to produce good hematologic response. Children may be given a total of 1 to 5 mg over a period of 2 or more weeks in doses of 100 mcg, then 30 to 50 mcg every 4 weeks for maintenance.</p>
<p>Patients who have normal intestinal absorption may be treated with an oral therapeutic multivitamin preparation, containing 15 mcg vitamin B<span class="Sub">12</span> daily.</p>
<p></p>
<p></p>
<p>The <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> dose is 1000 mcg.</p>
<p></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-10"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"></p>
<p>Hydroxocobalamin Injection USP, 1000 mcg/mL is available in a 30 mL multiple dose vial, individually boxed.</p>
<p></p>
<p></p>
<p>Store at 20°-25°C (68°-77°F). [See USP controlled room temperature.] <span class="Bold">PROTECT FROM LIGHT.</span></p>
<p>Literature revised: July 2010<br><br>Product No.: 0208-30</p>
<p>Manufactured by:<br><span class="Bold">Hikma Farmaceutica</span> (Portugal)<br>S.A. 2705-906 Terrugem SNT, Portugal<br><br>Distributed by:<br><span class="Bold">Watson Pharma, Inc.</span><br>Corona, CA 92880 USA                        <span class="Bold">PIN229-WAT/1</span></p>
<p></p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-11"></a><p></p>
<h1>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL SECTION</h1>
<p class="First">
    DRUG: Hydroxocobalamin </p>
<p><br></p>
<p>GENERIC: Hydroxocobalamin</p>
<p><br></p>
<p>DOSAGE: INJECTION, SOLUTION</p>
<p><br></p>
<p>ADMINSTRATION: INTRAMUSCULAR</p>
<p><br></p>
<p>NDC: 52125-799-01</p>
<p><br></p>
<p>ACTIVE INGREDIENT(S):</p>
<ul><li>HYDROXOCOBALAMIN ACETATE 1000ug in 1mL</li></ul>
<p><br></p>
<p>INACTIVE INGREDIENT(S):</p>
<ul>
<li>METHYLPARABEN</li>
<li>PROPYLPARABEN</li>
<li>SODIUM ACETATE ANHYDROUS</li>
<li>ACETIC ACID</li>
<li>SODIUM CHLORIDE</li>
<li>WATER</li>
</ul>
<p><br></p>
<p>PACKAGING: 30 mL in 1 VIAL, MULTI-DOSE</p>
<p><br></p>
<p><br></p>
<p><br></p>
<p><img alt="MM2" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d35ad609-70d3-4eb2-8276-c9631ca815d1&amp;name=MM2.jpg"></p>
<p><img alt="MM3" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=d35ad609-70d3-4eb2-8276-c9631ca815d1&amp;name=MM3.jpg"></p>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>HYDROXOCOBALAMIN 		
					</strong><br><span class="contentTableReg">hydroxocobalamin injection, solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:52125-799(NDC:0591-2888)</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>HYDROXOCOBALAMIN ACETATE</strong> (HYDROXOCOBALAMIN) </td>
<td class="formItem">HYDROXOCOBALAMIN</td>
<td class="formItem">1000 ug  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>METHYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>PROPYLPARABEN</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM ACETATE ANHYDROUS</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>ACETIC ACID</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM CHLORIDE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>WATER</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:52125-799-01</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem"></td>
<td class="formItem">30 mL in 1 VIAL, MULTI-DOSE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA085998</td>
<td class="formItem">12/31/2013</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>REMEDYREPACK INC. 
							(829572556)
						</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 12/2013<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>6dd2913f-4247-41c3-a7ba-94855b6e924a</div>
<div>Set id: d35ad609-70d3-4eb2-8276-c9631ca815d1</div>
<div>Version: 2</div>
<div>Effective Time: 20131231</div>
</div>
</div> <div class="DistributorName">REMEDYREPACK INC. </div></p>
</body></html>
